US4811161011 - Common Stock
JOUNCE THERAPEUTICS INC
NASDAQ:JNCE (5/3/2023, 7:26:07 PM)
After market: 1.92 +0.04 (+2.13%)1.88
-0.05 (-2.59%)
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
JOUNCE THERAPEUTICS INC
780 Memorial Drive
Cambridge MASSACHUSETTS 02139
P: 18572593840.0
CEO: Richard Murray
Employees: 141
Website: http://jouncetx.com/
Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Jounce Therapeutics (JNCE) announced that Concentra Biosciences agreed to acquire it for $1.85 in cash per share plus a contingent value right ((CVR)). Read more here.
Here you can normally see the latest stock twits on JNCE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: